Please login to the form below

Not currently logged in
Email:
Password:

Rubraca

This page shows the latest Rubraca news and features for those working in and with pharma, biotech and healthcare.

GSK upbeat on its return to oncology market

GSK upbeat on its return to oncology market

Co, with another rival Clovis’ Rubraca, also competing in the market.

Latest news

  • First-line ovarian approval cements AZ’s Lynparza lead First-line ovarian approval cements AZ’s Lynparza lead

    Lynparza is already well in front of its PARP inhibitor rivals, Tesaro’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib). ... tack, focusing its first-line maintenance efforts on a combination study of Rubraca with Bristol-Myers

  • Analysts lukewarm on GSK’s new cancer acquisition Analysts lukewarm on GSK’s new cancer acquisition

    leading rival Lynparza (olaparib) and two further entrants – Clovis Oncology’s Rubraca (rucaparib) and Pfizer’s Talzenna (talazoparib). ... Since then however Lynparza and Rubraca have both been approved for the same indication.

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    of the year – gives GSK rights to approved PARP inhibitor Zejula (niraparib), which is jostling for market share with AstraZeneca's Lynparza (olaparib) and Clovis Oncology's Rubraca (rucaparib). ... third quarter – well behind the $438m posted by

  • AZ and Clovis PARP inhibitors show their mettle at ESMO AZ and Clovis PARP inhibitors show their mettle at ESMO

    extend its lead over its PARP inhibitor rivals, Tesaro's Zejula (niraparib) and Clovis' Rubraca (rucaparib). ... Meanwhile, third-to-market Clovis has taken a slightly different tack, focusing its first-line maintenance efforts on a combination study of

  • China’s BeiGene raises $903m from Hong Kong IPO China’s BeiGene raises $903m from Hong Kong IPO

    It’s also in earlier-stage trials for other solid tumours, including glioblastoma.  It’s a potential rival to marketed PARP inhibitors from AstraZeneca (Lynparza), Clovis Oncology (Rubraca) and Tesaro (Zejula).

More from news
Approximately 6 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics